Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(RVPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Reviva Pharmaceuticals : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

09/02/2021 | 08:31am EDT

CUPERTINO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 23rd Annual Global Investment Conference as well as participate in one-on-one meetings with investors. The Conference will be held virtually with all participants joining remotely from September 13th - 15th.

H.C. Wainwright 23rd Annual Global Investment Conference
An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13th 2021 at 7am ET for 90 days after the event. A link to the live audio webcast as well as the replay of the webcast can be found below and will be available on Reviva’s website, under the “Investors- News & Events” section at https://ir.revivapharma.com/.

Webcast Link: https://journey.ct.events/view/e5a91398-5796-4cb0-b911-bcde078067ef

For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https://hcwevents.com/annualconference/. If you are interested in arranging a virtual one-on-one meeting, please contact your H.C. Wainwright representative or contact Bruce Mackle at LifeSciAdvisors.

About Reviva

Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com


Primary Logo

Source: Reviva Pharmaceuticals

2021 GlobeNewswire, Inc., source Press Releases

All news about REVIVA PHARMACEUTICALS HOLDINGS, INC.
09/20REVIVA PHARMACEUTICALS : Shareholder Director Nominations (Form 8-K)
PU
09/20REVIVA PHARMACEUTICALS HOLDINGS, INC : Shareholder Director Nominations (form 8-K)
AQ
09/15Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Confere..
GL
09/02REVIVA PHARMACEUTICALS : to Present at the H.C. Wainwright 23rd Annual Global Investment C..
AQ
08/16REVIVA PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Recent Business..
PU
08/16REVIVA PHARMACEUTICALS HOLDINGS, INC : Results of Operations and Financial Condition, Regu..
AQ
08/16REVIVA PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Recent Business..
AQ
08/16Reviva Pharmaceuticals Holdings, Inc. Announces Earnings Results for the Second Quarter..
CI
08/16REVIVA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
08/16Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter E..
CI
More news
Analyst Recommendations on REVIVA PHARMACEUTICALS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -11,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,17x
Yield 2021 -
Capitalization 47,1 M 47,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 5
Free-Float 59,7%
Chart REVIVA PHARMACEUTICALS HOLDINGS, INC.
Duration : Period :
Reviva Pharmaceuticals Holdings, Inc. Technical Analysis Chart | RVPH | US76152G1004 | MarketScreener
Technical analysis trends REVIVA PHARMACEUTICALS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 3,52 $
Average target price 14,50 $
Spread / Average Target 312%
EPS Revisions
Managers and Directors
Laxminarayan Bhat President, Chief Executive Officer & Director
Narayan Prabhu Chief Financial Officer
Parag Phoolchand Saxena Chairman
Marcus Cantillon Chief Medical Officer
Richard A. Margolin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REVIVA PHARMACEUTICALS HOLDINGS, INC.-59.75%47
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455